 Jeffrey Bennett
Concepts (491)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 73 | 2023 | 112 | 15.540 |
Why?
| | Aquaporin 4 | 52 | 2023 | 87 | 7.750 |
Why?
| | Multiple Sclerosis | 32 | 2023 | 384 | 6.620 |
Why?
| | Immunoglobulin G | 50 | 2023 | 788 | 4.850 |
Why?
| | Optic Neuritis | 15 | 2023 | 37 | 4.680 |
Why?
| | Autoantibodies | 44 | 2024 | 1335 | 4.600 |
Why?
| | B-Lymphocytes | 14 | 2023 | 770 | 1.790 |
Why?
| | Optic Nerve | 11 | 2023 | 65 | 1.790 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 32 | 1.750 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 15 | 2024 | 44 | 1.690 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 25 | 1.560 |
Why?
| | Astrocytes | 13 | 2022 | 177 | 1.410 |
Why?
| | Antibodies, Monoclonal, Humanized | 15 | 2023 | 667 | 1.180 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1284 | 1.170 |
Why?
| | Tomography, Optical Coherence | 6 | 2023 | 126 | 1.150 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 79 | 1.140 |
Why?
| | Neuroglia | 4 | 2018 | 157 | 1.120 |
Why?
| | Retinal Degeneration | 2 | 2023 | 31 | 0.970 |
Why?
| | Epitopes | 7 | 2023 | 443 | 0.940 |
Why?
| | Complement System Proteins | 7 | 2019 | 294 | 0.930 |
Why?
| | Natalizumab | 4 | 2020 | 46 | 0.920 |
Why?
| | Methylprednisolone | 1 | 2023 | 84 | 0.900 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 681 | 0.900 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 29 | 0.870 |
Why?
| | Humans | 127 | 2024 | 118972 | 0.860 |
Why?
| | Blood-Brain Barrier | 5 | 2022 | 108 | 0.850 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 72 | 0.820 |
Why?
| | Autoimmunity | 4 | 2017 | 831 | 0.810 |
Why?
| | Immunotherapy | 4 | 2020 | 493 | 0.780 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 32 | 0.760 |
Why?
| | Animals | 54 | 2023 | 33381 | 0.760 |
Why?
| | Cerebellum | 3 | 2018 | 203 | 0.750 |
Why?
| | Brain | 8 | 2019 | 2490 | 0.740 |
Why?
| | Disease Models, Animal | 14 | 2022 | 3730 | 0.710 |
Why?
| | Complement Activation | 4 | 2022 | 350 | 0.700 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 3 | 2023 | 50 | 0.700 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 19 | 0.690 |
Why?
| | Plasma Cells | 7 | 2017 | 59 | 0.690 |
Why?
| | Complement C1q | 1 | 2019 | 38 | 0.690 |
Why?
| | Inflammation | 11 | 2023 | 2566 | 0.680 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 22 | 0.680 |
Why?
| | Remyelination | 1 | 2018 | 9 | 0.670 |
Why?
| | Aminopyridines | 1 | 2019 | 85 | 0.660 |
Why?
| | Central Nervous System | 5 | 2023 | 245 | 0.660 |
Why?
| | Cell Membrane | 3 | 2017 | 710 | 0.650 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 68 | 0.650 |
Why?
| | Pyrroles | 1 | 2019 | 191 | 0.630 |
Why?
| | Microglia | 2 | 2019 | 221 | 0.630 |
Why?
| | Organic Chemicals | 1 | 2019 | 131 | 0.620 |
Why?
| | Immunologic Factors | 4 | 2022 | 225 | 0.620 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 56 | 0.610 |
Why?
| | Glucocorticoids | 2 | 2019 | 545 | 0.610 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 389 | 0.610 |
Why?
| | CHO Cells | 8 | 2019 | 143 | 0.600 |
Why?
| | Disease Management | 2 | 2018 | 571 | 0.600 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.590 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 129 | 0.580 |
Why?
| | Cricetulus | 7 | 2019 | 98 | 0.580 |
Why?
| | Myelin Sheath | 6 | 2023 | 148 | 0.570 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 36 | 0.570 |
Why?
| | Retina | 5 | 2023 | 278 | 0.570 |
Why?
| | Mice | 29 | 2023 | 15520 | 0.570 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1308 | 0.560 |
Why?
| | Mutagenesis | 2 | 2019 | 176 | 0.540 |
Why?
| | Stents | 2 | 2016 | 457 | 0.530 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 126 | 0.510 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 90 | 0.510 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 47 | 0.490 |
Why?
| | Optic Atrophy | 2 | 2011 | 11 | 0.480 |
Why?
| | Temporal Arteries | 4 | 2015 | 47 | 0.480 |
Why?
| | Visual Acuity | 6 | 2021 | 272 | 0.450 |
Why?
| | Flow Cytometry | 9 | 2023 | 1085 | 0.450 |
Why?
| | Papilledema | 3 | 2018 | 36 | 0.440 |
Why?
| | Antigens, Viral | 3 | 2015 | 181 | 0.440 |
Why?
| | Glial Fibrillary Acidic Protein | 4 | 2023 | 87 | 0.440 |
Why?
| | Magnetic Resonance Imaging | 9 | 2023 | 3174 | 0.440 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 92 | 0.430 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 45 | 0.420 |
Why?
| | Axons | 2 | 2022 | 185 | 0.420 |
Why?
| | Hemodynamics | 1 | 2016 | 1003 | 0.420 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 4 | 0.420 |
Why?
| | Recurrence | 7 | 2023 | 975 | 0.410 |
Why?
| | Cricetinae | 6 | 2019 | 262 | 0.400 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 73 | 0.400 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 39 | 0.400 |
Why?
| | Biomarkers | 8 | 2023 | 3588 | 0.400 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 149 | 0.390 |
Why?
| | Gene Targeting | 1 | 2011 | 80 | 0.390 |
Why?
| | Peptide Fragments | 3 | 2017 | 702 | 0.390 |
Why?
| | Nerve Degeneration | 1 | 2010 | 44 | 0.390 |
Why?
| | Spinal Cord | 7 | 2016 | 367 | 0.390 |
Why?
| | Adult | 32 | 2023 | 31512 | 0.390 |
Why?
| | Eye Diseases | 2 | 2020 | 77 | 0.390 |
Why?
| | Stilbenes | 1 | 2010 | 35 | 0.390 |
Why?
| | Nerve Regeneration | 1 | 2010 | 53 | 0.380 |
Why?
| | Antigens, CD19 | 4 | 2020 | 96 | 0.380 |
Why?
| | Mice, Inbred C57BL | 10 | 2023 | 4908 | 0.370 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 39 | 0.370 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 551 | 0.370 |
Why?
| | Middle Aged | 30 | 2021 | 27617 | 0.360 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 20 | 0.360 |
Why?
| | Immune System Phenomena | 1 | 2009 | 2 | 0.350 |
Why?
| | Female | 46 | 2022 | 61564 | 0.350 |
Why?
| | Virus Diseases | 1 | 2011 | 198 | 0.350 |
Why?
| | Rats | 12 | 2021 | 5392 | 0.340 |
Why?
| | Cell Survival | 2 | 2019 | 1047 | 0.340 |
Why?
| | Nervous System Diseases | 2 | 2020 | 261 | 0.330 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2071 | 0.330 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 87 | 0.320 |
Why?
| | Ophthalmology | 2 | 2007 | 80 | 0.320 |
Why?
| | Neurology | 2 | 2007 | 94 | 0.320 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 128 | 0.310 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 99 | 0.310 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1774 | 0.300 |
Why?
| | Antibodies | 3 | 2017 | 392 | 0.300 |
Why?
| | Proteomics | 2 | 2012 | 876 | 0.300 |
Why?
| | Mutation | 6 | 2019 | 3457 | 0.300 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 20 | 0.300 |
Why?
| | Immunization, Passive | 3 | 2020 | 81 | 0.290 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 46 | 0.290 |
Why?
| | Corpus Callosum | 1 | 2006 | 57 | 0.290 |
Why?
| | Antibody Formation | 1 | 2007 | 276 | 0.280 |
Why?
| | Protein Binding | 6 | 2019 | 1975 | 0.280 |
Why?
| | Atrophy | 2 | 2023 | 164 | 0.270 |
Why?
| | Herpes Zoster | 3 | 2015 | 336 | 0.270 |
Why?
| | Young Adult | 13 | 2023 | 10793 | 0.270 |
Why?
| | Syndecan-1 | 4 | 2011 | 30 | 0.260 |
Why?
| | Adolescent | 15 | 2021 | 18480 | 0.260 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.260 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 19 | 0.260 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 180 | 0.260 |
Why?
| | Male | 33 | 2022 | 57801 | 0.250 |
Why?
| | Acute Disease | 3 | 2018 | 940 | 0.250 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 46 | 0.250 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 27 | 0.240 |
Why?
| | Blindness, Cortical | 1 | 2003 | 5 | 0.240 |
Why?
| | Risk Assessment | 4 | 2021 | 3057 | 0.240 |
Why?
| | Peptide Library | 4 | 2011 | 80 | 0.240 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.240 |
Why?
| | Proteoglycans | 1 | 2004 | 109 | 0.240 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 170 | 0.230 |
Why?
| | Oligodendroglia | 2 | 2017 | 152 | 0.230 |
Why?
| | Prospective Studies | 8 | 2023 | 6471 | 0.230 |
Why?
| | Epitope Mapping | 4 | 2017 | 49 | 0.230 |
Why?
| | Neuroprotection | 1 | 2023 | 31 | 0.230 |
Why?
| | Seroconversion | 1 | 2023 | 48 | 0.230 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 827 | 0.220 |
Why?
| | Immune System | 1 | 2004 | 181 | 0.220 |
Why?
| | Vision Disorders | 2 | 2021 | 135 | 0.220 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 152 | 0.220 |
Why?
| | Cells, Cultured | 7 | 2016 | 4077 | 0.210 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2025 | 0.210 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 446 | 0.210 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2871 | 0.210 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 509 | 0.210 |
Why?
| | Protein Isoforms | 4 | 2017 | 345 | 0.200 |
Why?
| | Aged | 16 | 2021 | 19657 | 0.200 |
Why?
| | Autoantigens | 4 | 2020 | 397 | 0.200 |
Why?
| | Double-Blind Method | 6 | 2023 | 1687 | 0.200 |
Why?
| | Antibody Affinity | 2 | 2019 | 55 | 0.200 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 19 | 0.200 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1384 | 0.200 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 183 | 0.200 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 26 | 0.190 |
Why?
| | Internationality | 2 | 2019 | 152 | 0.190 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1067 | 0.190 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 35 | 0.190 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 36 | 0.190 |
Why?
| | Cell Proliferation | 3 | 2020 | 2275 | 0.190 |
Why?
| | Azathioprine | 1 | 2020 | 51 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2023 | 736 | 0.180 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 32 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2020 | 90 | 0.180 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.180 |
Why?
| | Cell Separation | 2 | 2015 | 296 | 0.180 |
Why?
| | Steroids | 1 | 2020 | 153 | 0.180 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 13 | 0.170 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 381 | 0.170 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 60 | 0.170 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 8 | 0.170 |
Why?
| | Communicable Diseases | 1 | 2020 | 132 | 0.170 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 9 | 0.170 |
Why?
| | Cell Lineage | 1 | 2020 | 318 | 0.170 |
Why?
| | Oxidoreductases | 1 | 2019 | 100 | 0.170 |
Why?
| | Peptides | 2 | 2019 | 879 | 0.170 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.160 |
Why?
| | Retrospective Studies | 9 | 2023 | 12978 | 0.160 |
Why?
| | Animals, Newborn | 2 | 2018 | 806 | 0.160 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 71 | 0.160 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 61 | 0.160 |
Why?
| | Point Mutation | 1 | 2019 | 228 | 0.160 |
Why?
| | Treatment Outcome | 10 | 2021 | 9342 | 0.160 |
Why?
| | Mice, Knockout | 9 | 2017 | 2680 | 0.160 |
Why?
| | Antibodies, Viral | 4 | 2023 | 542 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 702 | 0.150 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 453 | 0.150 |
Why?
| | Cohort Studies | 5 | 2022 | 5116 | 0.150 |
Why?
| | Skull Neoplasms | 1 | 2017 | 22 | 0.150 |
Why?
| | Spatial Analysis | 1 | 2017 | 25 | 0.150 |
Why?
| | Sphenoid Bone | 1 | 2017 | 16 | 0.150 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.150 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 73 | 0.150 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 42 | 0.150 |
Why?
| | Orbital Diseases | 1 | 2017 | 26 | 0.150 |
Why?
| | Albumins | 1 | 2017 | 100 | 0.150 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 95 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2016 | 4596 | 0.140 |
Why?
| | Microvessels | 1 | 2017 | 77 | 0.140 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 338 | 0.140 |
Why?
| | Fibrinogen | 1 | 2017 | 161 | 0.140 |
Why?
| | Interleukin-6 | 1 | 2020 | 688 | 0.140 |
Why?
| | HEK293 Cells | 4 | 2022 | 625 | 0.140 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6561 | 0.140 |
Why?
| | Meningioma | 1 | 2017 | 82 | 0.140 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 314 | 0.140 |
Why?
| | Ethics, Research | 1 | 2015 | 31 | 0.140 |
Why?
| | Child | 10 | 2022 | 19129 | 0.130 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 5 | 0.130 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 7 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 521 | 0.130 |
Why?
| | Treatment Failure | 1 | 2016 | 341 | 0.130 |
Why?
| | Retinal Neurons | 1 | 2015 | 3 | 0.130 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 213 | 0.130 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 412 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3360 | 0.130 |
Why?
| | Models, Molecular | 2 | 2017 | 1435 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 1 | 0.130 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 73 | 0.130 |
Why?
| | Visual Pathways | 2 | 2007 | 43 | 0.130 |
Why?
| | Alanine | 1 | 2015 | 102 | 0.130 |
Why?
| | Plasma Exchange | 1 | 2014 | 21 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2019 | 597 | 0.130 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 80 | 0.130 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 823 | 0.130 |
Why?
| | Nerve Fibers | 1 | 2015 | 89 | 0.120 |
Why?
| | Glycine | 1 | 2015 | 162 | 0.120 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 245 | 0.120 |
Why?
| | Erythropoietin | 1 | 2014 | 82 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 982 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1945 | 0.120 |
Why?
| | Transcriptome | 2 | 2020 | 756 | 0.120 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1597 | 0.120 |
Why?
| | Placenta Diseases | 1 | 2013 | 14 | 0.120 |
Why?
| | Fetal Death | 1 | 2013 | 52 | 0.120 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.120 |
Why?
| | Proteome | 2 | 2015 | 353 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2478 | 0.120 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 9 | 0.110 |
Why?
| | Antibody Specificity | 2 | 2011 | 184 | 0.110 |
Why?
| | Biomedical Research | 1 | 2019 | 612 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 1974 | 0.110 |
Why?
| | Phenotype | 3 | 2020 | 3003 | 0.110 |
Why?
| | Syndrome | 2 | 2019 | 344 | 0.110 |
Why?
| | Computer Simulation | 1 | 2017 | 922 | 0.110 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 25 | 0.110 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 88 | 0.110 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 149 | 0.110 |
Why?
| | Quality of Life | 1 | 2023 | 2366 | 0.110 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 97 | 0.110 |
Why?
| | Antigens, CD20 | 2 | 2023 | 28 | 0.110 |
Why?
| | Exanthema | 1 | 2013 | 77 | 0.110 |
Why?
| | Area Postrema | 1 | 2011 | 1 | 0.110 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 5 | 0.110 |
Why?
| | Drug Discovery | 1 | 2013 | 124 | 0.110 |
Why?
| | Cranial Sinuses | 1 | 2011 | 13 | 0.110 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 13 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1355 | 0.100 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 29 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 653 | 0.100 |
Why?
| | Fundus Oculi | 1 | 2011 | 41 | 0.100 |
Why?
| | Endothelial Cells | 1 | 2017 | 732 | 0.100 |
Why?
| | Cerebral Angiography | 2 | 2011 | 116 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2015 | 681 | 0.100 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 103 | 0.100 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 67 | 0.100 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 7 | 0.100 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.090 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 164 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2013 | 241 | 0.090 |
Why?
| | Spinal Puncture | 1 | 2009 | 16 | 0.090 |
Why?
| | Cell Line | 3 | 2011 | 2707 | 0.090 |
Why?
| | Databases, Factual | 1 | 2015 | 1231 | 0.090 |
Why?
| | Algorithms | 1 | 2017 | 1541 | 0.090 |
Why?
| | Research Design | 1 | 2015 | 969 | 0.090 |
Why?
| | Genes | 1 | 2009 | 231 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6412 | 0.080 |
Why?
| | Brain Injuries | 1 | 2014 | 484 | 0.080 |
Why?
| | Pregnancy Complications | 1 | 2013 | 448 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 35 | 0.080 |
Why?
| | Risk Factors | 3 | 2015 | 9000 | 0.080 |
Why?
| | Optic Disk | 1 | 2008 | 36 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2011 | 477 | 0.080 |
Why?
| | Clone Cells | 3 | 2017 | 248 | 0.080 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.080 |
Why?
| | Transfection | 3 | 2018 | 888 | 0.080 |
Why?
| | Retinal Artery | 1 | 2007 | 15 | 0.080 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 642 | 0.080 |
Why?
| | Age of Onset | 2 | 2020 | 467 | 0.080 |
Why?
| | Vision, Low | 1 | 2007 | 14 | 0.080 |
Why?
| | Interferon-beta | 1 | 2008 | 82 | 0.080 |
Why?
| | Visual Fields | 1 | 2007 | 78 | 0.080 |
Why?
| | Molecular Biology | 2 | 2009 | 58 | 0.080 |
Why?
| | Health | 1 | 2007 | 81 | 0.080 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 271 | 0.080 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.070 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.070 |
Why?
| | Measles virus | 1 | 2006 | 11 | 0.070 |
Why?
| | Bevacizumab | 1 | 2007 | 124 | 0.070 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 24 | 0.070 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 78 | 0.070 |
Why?
| | Vitreous Body | 1 | 2007 | 104 | 0.070 |
Why?
| | Puerperal Disorders | 1 | 2007 | 33 | 0.070 |
Why?
| | Binding, Competitive | 2 | 2019 | 205 | 0.070 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 49 | 0.070 |
Why?
| | Models, Immunological | 1 | 2006 | 94 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 219 | 0.070 |
Why?
| | Injections, Spinal | 2 | 2016 | 105 | 0.070 |
Why?
| | Immunologic Memory | 1 | 2007 | 313 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2851 | 0.070 |
Why?
| | Child, Preschool | 4 | 2021 | 9491 | 0.070 |
Why?
| | Fetus | 1 | 2009 | 690 | 0.070 |
Why?
| | Membrane Proteins | 1 | 2011 | 1055 | 0.070 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.060 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 220 | 0.060 |
Why?
| | DNA | 1 | 2011 | 1388 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 527 | 0.060 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 45 | 0.060 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 16 | 0.060 |
Why?
| | Granzymes | 1 | 2024 | 40 | 0.060 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 42 | 0.060 |
Why?
| | Risk | 1 | 2007 | 853 | 0.060 |
Why?
| | Patient Selection | 1 | 2008 | 676 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2006 | 749 | 0.060 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 204 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2023 | 67 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2275 | 0.060 |
Why?
| | Neurons | 3 | 2017 | 1345 | 0.060 |
Why?
| | Eye Abnormalities | 1 | 2002 | 10 | 0.060 |
Why?
| | Developmental Biology | 1 | 2002 | 18 | 0.060 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 95 | 0.060 |
Why?
| | Complement Inactivating Agents | 1 | 2023 | 43 | 0.050 |
Why?
| | Delphi Technique | 1 | 2023 | 164 | 0.050 |
Why?
| | Disease Progression | 3 | 2021 | 2490 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 60 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 133 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1079 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 46 | 0.050 |
Why?
| | Antigens, Surface | 1 | 2022 | 156 | 0.050 |
Why?
| | Eye | 1 | 2002 | 106 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 410 | 0.050 |
Why?
| | Glycoproteins | 1 | 2023 | 319 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 1224 | 0.050 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 31 | 0.050 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 7 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 534 | 0.050 |
Why?
| | COS Cells | 2 | 2011 | 184 | 0.050 |
Why?
| | Base Sequence | 1 | 2004 | 2159 | 0.050 |
Why?
| | Random Allocation | 1 | 2021 | 344 | 0.050 |
Why?
| | Pregnancy | 3 | 2013 | 5690 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2020 | 117 | 0.050 |
Why?
| | Immunomodulation | 1 | 2020 | 89 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 7 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2020 | 3171 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 155 | 0.040 |
Why?
| | Serum | 1 | 2019 | 63 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 726 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2021 | 280 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1715 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 159 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 7 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 55 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 842 | 0.040 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 254 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1267 | 0.040 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 15 | 0.040 |
Why?
| | Sequence Alignment | 2 | 2009 | 336 | 0.040 |
Why?
| | Clonal Deletion | 1 | 2017 | 18 | 0.040 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 15 | 0.040 |
Why?
| | Recovery of Function | 1 | 2021 | 604 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 146 | 0.040 |
Why?
| | Craniotomy | 1 | 2017 | 69 | 0.040 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 200 | 0.040 |
Why?
| | Th17 Cells | 1 | 2016 | 57 | 0.040 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 133 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2011 | 1293 | 0.040 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 138 | 0.040 |
Why?
| | Lipid Bilayers | 1 | 2017 | 100 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 3 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 161 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1636 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 500 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 462 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 827 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 339 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 290 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 355 | 0.030 |
Why?
| | Parkinson Disease | 1 | 2019 | 334 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 43 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 392 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 39 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 510 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 334 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 219 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 21 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 35 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 18 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 63 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2003 | 2436 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2995 | 0.030 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 185 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 398 | 0.030 |
Why?
| | Narcolepsy | 1 | 2013 | 18 | 0.030 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 20 | 0.030 |
Why?
| | Pyrans | 1 | 2012 | 4 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 632 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 180 | 0.030 |
Why?
| | Vaccination | 1 | 2020 | 1222 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 101 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2513 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 85 | 0.030 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 38 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 2015 | 416 | 0.030 |
Why?
| | Phlebography | 1 | 2011 | 40 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 219 | 0.030 |
Why?
| | O Antigens | 1 | 2011 | 9 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2674 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2011 | 210 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 195 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 522 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 280 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1419 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 63 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 122 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 567 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 334 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 134 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 122 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 220 | 0.020 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2013 | 227 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 969 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1785 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 217 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 122 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 38 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1527 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 34 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 8 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 654 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 363 | 0.020 |
Why?
| | Water | 1 | 2012 | 425 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2009 | 154 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 140 | 0.020 |
Why?
| | B-Lymphocyte Subsets | 1 | 2009 | 66 | 0.020 |
Why?
| | Virion | 1 | 2009 | 78 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2326 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 348 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 297 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 253 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 828 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 408 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 513 | 0.020 |
Why?
| | Glioma | 1 | 2010 | 306 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 356 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2424 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 984 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1206 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1900 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 736 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 4552 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1167 | 0.020 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 6 | 0.020 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 9 | 0.020 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 10 | 0.020 |
Why?
| | Infant | 1 | 2017 | 8293 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 755 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1169 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 693 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 588 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1244 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2445 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1440 | 0.010 |
Why?
| | Signal Transduction | 1 | 2009 | 4709 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 4708 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|